FDA nixes Sanofi's Lemtrada; Genzyme plans appeal
This article was originally published in Scrip
The FDA has refused to approve Sanofi/ Genzyme's monoclonal antibody product for multiple sclerosis, Lemtrada (alemtuzumab). In a complete response letter, the US agency says the company had not satisfactorily proven that the product's benefits outweigh its serious adverse effects. It will require further trials before the reconsidering Lemtrada's suitability for marketing in the US.
You may also be interested in...
INFOGRAPHIC: In 2019, 10 blockbuster medicines booked combined sales of $92.5bn. This infographic examines those drugs that commanded the greatest revenues globally, and answers some key questions. Which therapeutic areas include the most lucrative blockbusters? Which companies enjoyed their spoils? And which drugs were new to the top 10 last year? It also takes a look at the position of these products on the all-important US market.
Fundraising in the life sciences sector has been booming even as firms in many other industries are struggling to stay in business. Goodwin’s David Mardle is upbeat about the sector’s ongoing prospects – although M&A deals are currently proving tricky to complete.
See how much the CEOs and R&D heads of the world’s biggest pharma companies get paid, and how those companies are performing.